All Trials

A Phase I Study of Autologous Activated T-Cells Expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch Administered To Patients With Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: For pediatric and adult patients with relapsed/refractory high-risk neuroblastoma/ganglioneuroblastoma or osteosarcoma, after standard therapies. Patients receive lymphodepleting cyclophosphamide/fludarabine followed by a single infusion of autologous GD2-directed CAR T cells engineered to co-express IL-15 (to enhance persistence/function) and an inducible caspase-9 safety switch.

ClinicalTrials.gov ID: NCT03721068

A Phase I, Multicentre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with CNS tumors receiving radiotherapy: recurrent/relapsed GBM (IMRT 35 Gy/2 weeks) and newly diagnosed GBM with unmethylated MGMT (IMRT 60 Gy/6 weeks) are treated with concurrent oral AZD1390, a brain-penetrant ATM kinase inhibitor radiosensitizer; the closed arm previously enrolled patients with brain metastases not suitable for SRS. Key eligibility includes KPS ≥60 and MRI suitability; exclusions include strong CYP3A4 modulators and significant comorbidities.

ClinicalTrials.gov ID: NCT03423628

A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Subjects With Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with mesothelin-expressing recurrent/relapsed advanced ovarian (including primary peritoneal/fallopian tube), cholangiocarcinoma, or epithelial mesothelioma (pleural/peritoneal), ECOG 0–1, after ≥1 prior therapy, receive lymphodepleting chemotherapy followed by a single infusion of SynKIR-110, an autologous T-cell therapy using a mesothelin-targeted KIR-CAR (activating KIR plus DAP12) designed to enhance persistence/function in solid tumors. Excludes prior gene-engineered T-cell therapy, sarcomatoid/biphasic mesothelioma, active viral infections, significant pulmonary disease, and active autoimmune disease.

ClinicalTrials.gov ID: NCT05568680

Phase I/II Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults and adolescents (16–80 years) with CD70-positive advanced clear cell RCC (post PD-1/PD-L1 and anti-angiogenic therapy), mesothelioma (progressive after standard options including checkpoint blockade), or osteosarcoma (recurrent/refractory after anthracycline) receive fludarabine/cyclophosphamide lymphodepletion followed by a single infusion of allogeneic cord blood–derived CAR NK cells targeting CD70 via a CD27-based CAR, armored with IL-15 for persistence and containing an inducible caspase-9 safety switch. Single-arm dose-escalation/expansion evaluates safety, dose, persistence, and preliminary activity.

ClinicalTrials.gov ID: NCT05703854

A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced, refractory solid tumors (ECOG 0–1) lacking standard options receive the oral GLS1 inhibitor IACS-6274 either as monotherapy or combined with bevacizumab plus weekly paclitaxel or with the AKT inhibitor capivasertib. Biomarker-enriched cohorts include platinum-resistant high-grade serous ovarian cancer with low ASNS and tumors (including NSCLC) harboring KEAP1/NFE2L2/STK11/NF1 or PI3K/AKT/PTEN pathway alterations.

ClinicalTrials.gov ID: NCT05039801

Pilot Pharmacokinetic Study of VAL-413 (Orotecan®) in Patients With Recurrent Pediatric Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling children, adolescents, and young adults (1–≤30 years) with recurrent/refractory solid or CNS tumors lacking curative options, including those previously exposed to irinotecan/temozolomide if not refractory. Patients receive a flavored oral irinotecan formulation (VAL-413, prodrug converted to SN-38 topoisomerase I inhibitor) plus oral temozolomide in 5-day, 21-day cycles, with a cycle 1 PK comparison dose of orally administered IV irinotecan solution.

ClinicalTrials.gov ID: NCT04337177

A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Relapsed/refractory pediatric and young adult sarcomas (osteosarcoma, Ewing, rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue; ages 2–40) receive gemcitabine/docetaxel plus off‑the‑shelf, ex vivo expanded TGFβ‑imprinted universal donor NK cells designed to resist TGFβ-mediated suppression in the tumor microenvironment. NK infusions are given on day 12 of 21‑day cycles (up to 6 NK doses within 8 chemotherapy cycles) with safety and 6‑month PFS assessed.

ClinicalTrials.gov ID: NCT05634369

A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic prostate adenocarcinoma (ECOG 0–1) post–second-generation AR therapy and typically post-taxane (or ineligible/refusing), with PARP inhibitor exposure if BRCA1/2-mutated, receive oral RO7656594 (GDC-2992), a heterobifunctional androgen receptor antagonist/degrader via cereblon-mediated proteasomal degradation. Dose escalation and expansion assess safety, PK, and preliminary activity, excluding prior AR degrader exposure and untreated CNS disease.

ClinicalTrials.gov ID: NCT05800665

A Phase 1 Study of EP31670, a Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling adults with ECOG 0–1 who have selected relapsed/refractory cancers: solid tumors (e.g., post–docetaxel/AR-targeted mCRPC or metastatic/unresectable NUT carcinoma) and hematologic malignancies including CMML and intermediate/high-risk myelofibrosis after JAK inhibitor; stable treated brain mets allowed. Investigational therapy is EP31670 (NEO2734), an oral first-in-class dual BET and CBP/p300 inhibitor given intermittently as monotherapy (solid tumors/CMML) or combined with ruxolitinib or momelotinib in myelofibrosis.

ClinicalTrials.gov ID: NCT05488548

A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 (Spevatamig) Followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination With ChemotherApy, and/or an Immune ChecKpoint Inhibitor. The TWINPEAK Study

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable/metastatic CLDN18.2-positive gastric/GEJ, pancreatic ductal, or biliary tract adenocarcinomas receive spevatamig (PT886)—a bispecific antibody targeting CLDN18.2 and CD47 to enhance macrophage-mediated phagocytosis—given as monotherapy or combined with chemotherapy (e.g., paclitaxel, gemcitabine/nab-paclitaxel, FOLFOX, CAPOX, FOLFIRINOX) and/or pembrolizumab. Cohorts are line- and disease-specific, with CLDN18.2 expression ≥10% at ≥2+ required for combination parts.

ClinicalTrials.gov ID: NCT05482893